Drug manufacturers Aurobindo Pharma, Glenmark Pharmaceuticals, and FDC Ltd. are recalling products from the US market due to various manufacturing issues, according to recent reports from the US Food and Drug Administration (USFDA).

Aurobindo Pharma USA Inc., a subsidiary of the Hyderabad-based pharmaceutical giant Aurobindo Pharma, is recalling 240 bottles of its Healthy Living Acetaminophen, Aspirin (NSAID), and caffeine tablets. The recall, as detailed in the latest USFDA enforcement report, is due to a labeling issue where the affected lot was found to be missing essential product information on the label.

In addition to Aurobindo, Glenmark Pharmaceuticals and FDC Ltd. have also issued recalls for their products. While specific details about the Glenmark and FDC recalls were not immediately provided, these actions typically stem from quality control issues, labeling errors, or other manufacturing concerns that could affect product safety or efficacy.

The recalls underscore the ongoing scrutiny of pharmaceutical products by regulatory agencies to ensure compliance with safety standards and protect consumer health. Companies involved in the recalls are working closely with the USFDA to address the issues and prevent future occurrences.

Consumers who have purchased the recalled products are advised to stop using them immediately and contact the respective companies for further instructions. This action is part of a broader effort to maintain high standards of drug safety and quality in the marketplace.